Drugs / Suraxavir marboxil
Suraxavir marboxil
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04736758 | Jan → Dec 2021 | influenza | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07236814 | Nov 2025 → Mar 2027 expected | influenza | Capital Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT07113392 | Aug 2025 → Aug 2026 overdue | influenza | Jiangxi Kvvit Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05474755 | Jul 2022 → Apr 2023 | influenza | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Suraxavir Marboxil | “This study aimed to evaluate the therapeutic effect of suraxavir marboxil (GP681, abbreviated as suraxavir) in adults with uncomplicated influenza.” PMID 39870350 ↗ Jan 20253“Suraxavir marboxil (GP681) is an antiviral drug inhibiting the polymerase acidic protein (PA) of RNA polymerase, of influenza.” PMID 39775042 ↗ Jan 2025 |
| Known as | GP681 | “This study aimed to evaluate the therapeutic effect of suraxavir marboxil (GP681, abbreviated as suraxavir) in adults with uncomplicated influenza.” PMID 39870350 ↗ Jan 20251“Suraxavir marboxil (GP681) is an antiviral drug inhibiting the polymerase acidic protein (PA) of RNA polymerase, of influenza.” PMID 39775042 ↗ Jan 2025 |
| Known as | suraxavir | “This study aimed to evaluate the therapeutic effect of suraxavir marboxil (GP681, abbreviated as suraxavir) in adults with uncomplicated influenza.” PMID 39870350 ↗ Jan 2025 |
| Route | Oral | “Patients in the GP681 tablet 40mg group is treated with GP681 tablet 40mg orally once with 240mL water.” NCT04736758 ↗ |